Dysfunctional antigen-specific cd8+ t cells in the tumor microenvironment
AssigneeThe University of Chicago
InventorsThomas Gajewski, Jason Williams, Brendan Horton
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods for detecting and/or targeting dysfunctional tumor antigen-specific CD8+ T cells in the tumor microenvironment for diagnostic, therapeutic and/or research applications. In particular, dysfunctional tumor antigen-specific CD8+ T cells are detected and/or targeted via their expression of cell surface receptors described herein, such as 4-1BB, LAG-3, or additional markers that correlate with 4-1BB and LAG-3 expression, such as markers differentially expressed on the surface of the T cells.
Claims24
A method of treating a subject with cancer comprising administering an agent that specifically targets dysfunctional tumor antigen-specific CD8+ T cells.
A composition comprising:
- (a) one or more of an anti-4-1BB agent, an anti-LAG-3 agent, an anti-Nrn1 agent, an anti-Sema7a agent, and an anti-CRTAM agent;
- and (b) an immunotherapeutic agent, said composition formulated for therapeutic delivery to a subject.
A method comprising:
- (a) testing CD8+ T cells from a cell population to determine whether they co-express LAG-3 and 4-1BB;
- and (b) administering an anti-Nrn1 agent, an anti-Sema7a agent, and an anti-CRTAM agent.
A method of identifying dysfunctional T cells by testing said cells for co-expression of 4-1BB and LAG-3.
Dependencies are inferred from the claim text.